Alexander Locke

Dr. Alexander Locke

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SDShrutikona Das
Shrutikona Das
NWNicolas Wentzensen
Nicolas Wentzensen
GSGeorge F Sawaya
George F Sawaya
DEDidem Egemen
Didem Egemen
ALAlexander Locke
Alexander Locke
LCLi Cheung
Li Cheung
Implementation of primary human papillomavirus (HPV) testing has been slow in the United States perhaps because of concerns of decreased sensitivity compared with concurrent HPV and cytology testing (“cotesting”). We used the National Breast and Cervical Cancer Early Detection Program and the Kaiser Permanente of Northern California cohort to quantify potential trade-offs with primary HPV compared with cotesting in 4 US populations with differing precancer or cancer prevalence. In all settings, cotesting required more lab tests and more colposcopies compared with primary HPV testing. Additional cervical intraepithelial neoplasia grade 3 or cancer immediately detected from cotesting vs primary HPV decreased with decreasing population-average cervical intraepithelial neoplasia grade 3 or cancer prevalence from 71 per 100 000 screened among never or rarely screened individuals in the National Breast and Cervical Cancer Early Detection Program (prevalence = 1212 per 100 000) to 4 per 100 000 screened among individuals with prior HPV-negative results in Kaiser Permanente of Northern California (prevalence = 86 per 100 000). These data suggest that cotesting confer an unfavorable benefit-to-harm ratio over primary HPV testing.

8 September 2021 in Obstetrics & Gynecology
Verified
Journal Article
Open access
ALAlexander Locke
Alexander Locke
NSNina R. Shah
Nina R. Shah
BFBarbara Sct (Asccp) Fetterman
Barbara Sct (Asccp) Fetterman
NPNancy Bs Poitras
Nancy Bs Poitras
SWSoora Wi
Soora Wi
TLThomas Lorey
Thomas Lorey
The majority of cervical cancers after Pap-test–positive, human papillomavirus test–negative co-tests are symptomatic or clinically apparent.

Verified
Journal Article
Open access
PDF file
AGAndrew Goulian
Andrew Goulian
IWIsaac Wilson
Isaac Wilson
ALAlexander Locke
Alexander Locke
Background/Objectives: Lower circulating testosterone concentrations in postmenopausal women have been associated with adverse sexual, skeletal, and metabolic outcomes, yet population-level prevalence estimates remain inconsistent. In the absence of universally accepted diagnostic thresholds for androgen deficiency in women, interpretation of serum testosterone concentrations remains variable. This study aimed to describe the distribution of serum total testosterone and to evaluate demographic and hormonal correlates among physiologic postmenopausal women in the United States. Methods: This cross-sectional study analyzed women meeting criteria for physiologic menopause from the 2011–2016 and 2021–2023 National Health and Nutrition Examination Survey (NHANES) cycles. Participants using androgenic medications were excluded. Because no universally accepted diagnostic threshold exists for testosterone deficiency in women, serum total testosterone <30 ng/dL was used as an operational, population-based reference point, with <20 ng/dL evaluated as a sensitivity threshold. Survey-weighted analyses characterized the cohort and examined associations between testosterone concentrations below the <30 ng/dL operational threshold and demographic and hormonal variables using logistic regression. Results: Among 2707 postmenopausal women, the weighted mean total testosterone was 25.2 ± 1.1 ng/dL. Using operational, distribution-based thresholds, 56.0% of women had testosterone concentrations <20 ng/dL and 79.9% had concentrations <30 ng/dL (Rao–Scott χ2, p < 0.001). In the weighted distribution, both thresholds lay above the weighted median, with 30 ng/dL exceeding the 75th percentile. The proportion of women with testosterone concentrations below the <30 ng/dL threshold differed significantly by race/ethnicity (p < 0.01) and age group (p < 0.01), highest among Non-Hispanic Asian (87.7%) and Mexican American (89.4%) women and lowest among Non-Hispanic Black women (75.5%). In multivariable models, higher sex hormone binding globulin (SHBG) (adjusted OR = 0.720; 95% CI: 0.633–0.820; p < 0.001) and higher estradiol (adjusted OR = 0.577; 95% CI: 0.389–0.856; p < 0.05) were independently associated with lower odds of testosterone concentrations below the <30 ng/dL threshold. Conclusions: Testosterone concentrations below operational thresholds are highly prevalent among U.S. postmenopausal women, although estimates vary depending on the cutoff applied. Higher SHBG and estradiol levels were inversely associated with testosterone concentrations below these thresholds, underscoring the physiologic interrelationship of these hormones in postmenopausal women. These findings highlight the need for standardized, population-specific reference thresholds and clearer clinical frameworks for interpreting androgen levels in women.